{"id":"NCT05355818","sponsor":"LEO Pharma","briefTitle":"Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema","officialTitle":"A Phase 3 Clinical Trial to Evaluate Efficacy and Safety of Twice-daily Applications of Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-07-14","primaryCompletion":"2024-12-05","completion":"2024-12-17","firstPosted":"2022-05-02","resultsPosted":"2025-07-02","lastUpdate":"2025-07-29"},"enrollment":98,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hand Eczema"],"interventions":[{"type":"DRUG","name":"Delgocitinib","otherNames":[]},{"type":"DRUG","name":"Cream vehicle","otherNames":[]}],"arms":[{"label":"Delgocitinib cream","type":"EXPERIMENTAL"},{"label":"Cream vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this trial is to test if delgocitinib cream is effective in treating chronic hand eczema (CHE) and to find out what side effects it may have compared with a cream vehicle with no active medical ingredient in adolescents aged 12-17 years. At each visit to the clinic, the doctor will assess the severity and extent of CHE, and during the trial, the adolescents will assess their CHE signs and symptoms as well as quality of life.\n\nThe trial will last up to 22 weeks and has a 1-4 week screening period, a 16-week treatment period and a 2- week follow-up period. During the treatment period, each adolescent participant will use either the delgocitinib cream or cream vehicle twice daily.","primaryOutcome":{"measure":"Number of Participants With IGA-CHE Treatment Success at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Delgocitinib Cream","deltaMin":47,"sd":null},{"arm":"Cream Vehicle","deltaMin":7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":37,"countries":["Australia","Belgium","Canada","France","Poland","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":74},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache"]}}